Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


Efficacy and Safety of Once-Weekly versus Twice-Weekly Bortezomib in Patients with Hematologic Malignancies: A Meta-analysis with Trial Sequential Analysis.

Hu B, Zhou Q, Hu YY, Zhuang L, Yi LP, Cao JX, Li TQ, Wang J.

Pharmacotherapy. 2019 Jun;39(6):697-708. doi: 10.1002/phar.2267. Epub 2019 May 8.


Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, Gentili S, Patriarca F, Nozzoli C, Levi A, Guglielmelli T, Benevolo G, Callea V, Rizzo V, Cangialosi C, Musto P, De Rosa L, Liberati AM, Grasso M, Falcone AP, Evangelista A, Cavo M, Gaidano G, Boccadoro M, Palumbo A.

Blood. 2010 Dec 2;116(23):4745-53. doi: 10.1182/blood-2010-07-294983. Epub 2010 Aug 31. Erratum in: Blood. 2012 Dec 20;120(26):5250.


Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis

Hu B, Zhou Q, Wu T, Zhuang L, Yi L, Cao J, Yang X, Wang J.

Int J Clin Pharmacol Ther. 2017 Apr;55(4):329-338. doi: 10.5414/CP202714. Review.


Bortezomib for the treatment of multiple myeloma.

Scott K, Hayden PJ, Will A, Wheatley K, Coyne I.

Cochrane Database Syst Rev. 2016 Apr 20;4:CD010816. doi: 10.1002/14651858.CD010816.pub2. Review.


Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.

Yu YF, Wang Y, Fu TP, Chen K, Liu JQ, Yao HR.

Breast Cancer Res Treat. 2018 Apr;168(2):337-348. doi: 10.1007/s10549-017-4592-y. Epub 2017 Nov 29.


Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.

Gerecitano J, Portlock C, Hamlin P, Moskowitz CH, Noy A, Straus D, Schulman P, Dumitrescu O, Sarasohn D, Pappanicholaou J, Iasonos A, Zhang Z, Mo Q, Horanlli E, Rojas CN, Zelenetz AD, O'Connor OA.

Clin Cancer Res. 2011 Apr 15;17(8):2493-501. doi: 10.1158/1078-0432.CCR-10-1498. Epub 2011 Feb 23.


Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.

Mateos MV, Bringhen S, Richardson PG, Lahuerta JJ, Larocca A, Oriol A, Boccadoro M, García-Sanz R, Di Raimondo F, Esseltine DL, van de Velde H, Desai A, Londhe A, San Miguel JF, Palumbo A.

Haematologica. 2014 Jun;99(6):1114-22. doi: 10.3324/haematol.2013.099341. Epub 2014 Apr 24.


Once- versus twice-weekly Bortezomib induction therapy with dexamethasone in newly diagnosed multiple myeloma.

Wang Y, Ai L, Cui G, Gowrea B, Li M, Hu Y.

J Huazhong Univ Sci Technolog Med Sci. 2012 Aug;32(4):495-500. doi: 10.1007/s11596-012-0086-7. Epub 2012 Aug 11.


Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.

Sidana S, Narkhede M, Elson P, Hastings D, Faiman B, Valent J, Samaras C, Hamilton K, Liu HK, Smith MR, Reu FJ.

PLoS One. 2017 Mar 9;12(3):e0172996. doi: 10.1371/journal.pone.0172996. eCollection 2017.


Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.

Fukushima T, Nakamura T, Iwao H, Nakajima A, Miki M, Sato T, Sakai T, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Nakajima H, Motoo Y, Umehara H.

Anticancer Res. 2011 Jun;31(6):2297-302.


Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.

Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, Dimopoulos MA, Huang M, Zahlten-Kumeli A, Stewart AK.

Lancet Oncol. 2018 Jul;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1. Epub 2018 Jun 1. Erratum in: Lancet Oncol. 2018 Aug;19(8):e382.


Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.

Luo W, Wang Z, Tian P, Li W.

J Cancer Res Clin Oncol. 2018 Oct;144(10):1851-1859. doi: 10.1007/s00432-018-2707-4. Epub 2018 Jul 17. Review.


Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L.

Cochrane Database Syst Rev. 2017 Dec 22;12:CD011535. doi: 10.1002/14651858.CD011535.pub2. Review.


Early enteral nutrition within 24 hours of lower gastrointestinal surgery versus later commencement for length of hospital stay and postoperative complications.

Herbert G, Perry R, Andersen HK, Atkinson C, Penfold C, Lewis SJ, Ness AR, Thomas S.

Cochrane Database Syst Rev. 2018 Oct 24;10:CD004080. doi: 10.1002/14651858.CD004080.pub3.


Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.

Goldenberg JZ, Yap C, Lytvyn L, Lo CK, Beardsley J, Mertz D, Johnston BC.

Cochrane Database Syst Rev. 2017 Dec 19;12:CD006095. doi: 10.1002/14651858.CD006095.pub4. Review.


A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.

Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA.

Clin Cancer Res. 2005 May 1;11(9):3410-6.


Subfascial endoscopic perforator surgery (SEPS) for treating venous leg ulcers.

Lin ZC, Loveland PM, Johnston RV, Bruce M, Weller CD.

Cochrane Database Syst Rev. 2019 Mar 3;3:CD012164. doi: 10.1002/14651858.CD012164.pub2.


Thromboprophylaxis With Apixaban in Patients Undergoing Major Orthopedic Surgery: Meta-Analysis and Trial-Sequential Analysis.

Caldeira D, Rodrigues FB, Pinto FJ, Ferreira JJ, Costa J.

Clin Med Insights Blood Disord. 2017 May 8;10:1179545X17704660. doi: 10.1177/1179545X17704660. eCollection 2017. Review.

Supplemental Content

Support Center